REPLIMUNE GROUP, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
REPLIMUNE GROUP, INC. (REPL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $10.18 million for the 12-month period ending 2021-03-31, per its 10-K filed 2021-05-20.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2021-05-20
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2021-03-31 was $1.85M, a 92.92% increase year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-12-31 was $2.07M, a 94.64% increase year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-09-30 was $1.63M, a 49.22% decline year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-06-30 was $4.63M, a 2095.73% increase year-over-year.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $10.18M, a 87.17% increase from fiscal 2020.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2020 was $5.44M, a 319.11% increase from fiscal 2019.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $1.30M, a 226.13% increase from fiscal 2018.
- REPLIMUNE GROUP, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $398.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2021-03-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | $3.92M derived: sum of 2 quarters · filed 2021-05-20 | $5.55M derived: sum of 3 quarters · filed 2021-05-20 | $10.18M 10-K · filed 2021-05-20 |
| 2020-12-31 | $2.07M 10-Q · filed 2021-02-04 | $3.70M derived: sum of 2 quarters · filed 2021-02-04 | $8.33M 10-Q · filed 2021-02-04 | $9.29M derived: sum of 4 quarters · filed 2021-05-20 |
| 2020-09-30 | $1.63M 10-Q · filed 2020-11-05 | $6.26M 10-Q · filed 2020-11-05 | $7.22M derived: sum of 3 quarters · filed 2021-05-20 | $8.28M derived: sum of 4 quarters · filed 2021-05-20 |
| 2020-06-30 | $4.63M 10-Q · filed 2020-08-07 | $5.59M derived: sum of 2 quarters · filed 2021-05-20 | $6.66M derived: sum of 3 quarters · filed 2021-05-20 | $9.86M derived: sum of 4 quarters · filed 2021-05-20 |
| 2020-03-31 | $960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | $2.02M derived: sum of 2 quarters · filed 2021-05-20 | $5.23M derived: sum of 3 quarters · filed 2021-05-20 | $5.44M 10-K · filed 2021-05-20 |
| 2019-12-31 | $1.06M 10-Q · filed 2021-02-04 | $4.27M derived: sum of 2 quarters · filed 2021-02-04 | $4.48M 10-Q · filed 2021-02-04 | $4.74M derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-09-30 | $3.21M 10-Q · filed 2020-11-05 | $3.42M 10-Q · filed 2020-11-05 | $3.67M derived: sum of 3 quarters · filed 2020-11-05 | $3.88M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $211.00K 10-Q · filed 2020-08-07 | $467.00K derived: sum of 2 quarters · filed 2020-08-07 | $678.00K derived: sum of 3 quarters · filed 2020-08-07 | $1.46M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $256.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $467.00K derived: sum of 2 quarters · filed 2020-06-03 | $1.25M derived: sum of 3 quarters · filed 2020-06-03 | $1.30M 10-K · filed 2020-06-03 |
| 2018-12-31 | $211.00K 10-Q · filed 2020-02-13 | $996.00K derived: sum of 2 quarters · filed 2020-02-13 | $1.04M 10-Q · filed 2020-02-13 | $1.27M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-09-30 | $785.00K 10-Q · filed 2019-11-12 | $830.00K 10-Q · filed 2019-11-12 | $1.06M derived: sum of 3 quarters · filed 2019-11-12 | $1.11M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $45.00K 10-Q · filed 2019-08-14 | $271.00K derived: sum of 2 quarters · filed 2019-08-14 | $325.00K derived: sum of 3 quarters · filed 2019-08-14 | $379.00K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-06-28 | $280.00K derived: sum of 2 quarters · filed 2019-06-28 | $334.00K derived: sum of 3 quarters · filed 2019-06-28 | $398.00K 10-K · filed 2019-06-28 |
| 2017-12-31 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-14 | $108.00K derived: sum of 2 quarters · filed 2019-02-14 | $172.00K 10-Q · filed 2019-02-14 | |
| 2017-09-30 | $54.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-11-14 | $118.00K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $64.00K 10-Q · filed 2018-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |